Literature DB >> 10669155

Hemostatic parameters and platelet activation marker expression in cyanotic and acyanotic pediatric patients undergoing cardiac surgery in the presence of tranexamic acid.

E Levin1, J Wu, D V Devine, J Alexander, C Reichart, S Sett, M Seear.   

Abstract

We have investigated hemostatic parameters including platelet activation in 56 pediatric patients with or without cyanosis undergoing cardiopulmonary bypass (CPB) and cardiac surgery to repair congenital defects. Patients were participants in a study assessing the effects of tranexamic acid on surgery-related blood loss. Parameters monitored included blood loss, prothrombin F1.2, thrombin-antithrombin complexes, t-PA, PAI-1, plasminogen, fibrin D-dimer, and plasma factor XIII. Additionally, flow cytometry monitored platelet degranulation (P-selectin or CD63), as well as surface-bound fibrinogen, von Willebrand factor and factor XIIIa. Cyanotic patients had evidence of supranormal coagulation activation as both fibrin D-dimer and PAI-1 levels were elevated prior to surgery. While the extent of expression of P-selectin or CD63 was not informative, platelet-associated factor XIIIa was elevated in cyanotic patients at baseline. In both patient groups, CPB altered platelet activation state and coagulation status irrespective of the use of tranexamic acid.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669155

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Effect of tranexamic acid on blood loss in pediatric cardiac surgery: a randomized trial.

Authors:  Kazuyoshi Shimizu; Yuichiro Toda; Tatsuo Iwasaki; Mamoru Takeuchi; Hiroshi Morimatsu; Moritoki Egi; Tomohiko Suemori; Satoshi Suzuki; Kiyoshi Morita; Shunji Sano
Journal:  J Anesth       Date:  2011-09-24       Impact factor: 2.078

Review 2.  Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery.

Authors:  Colleen E Gruenwald; Cedric Manlhiot; Lynn Crawford-Lean; Celeste Foreman; Leonardo R Brandão; Brian W McCrindle; Helen Holtby; Ross Richards; Helen Moriarty; Glen Van Arsdell; Anthony K Chan
Journal:  J Extra Corpor Technol       Date:  2010-03

3.  Dynamics of factor XIII levels after open heart surgery for congenital heart defects: do cyanotic and acyanotic patients differ?

Authors:  Leo A Bockeria; Natalia N Samsonova; Ivan A Yurlov; Ludmila G Klimovich; Elena F Kozar; Eva H N Olsen; Sergey B Zaets
Journal:  Pediatr Cardiol       Date:  2014-04-09       Impact factor: 1.655

Review 4.  A systematic review of the use of antifibrinolytic agents in pediatric surgery and implications for craniofacial use.

Authors:  Marten N Basta; Paul A Stricker; Jesse A Taylor
Journal:  Pediatr Surg Int       Date:  2012-09-01       Impact factor: 1.827

5.  Acute Ischemic Pediatric Stroke Management: An Extended Window for Mechanical Thrombectomy?

Authors:  Ashish Kulhari; Elizabeth Dorn; Jonathan Pace; Vilakshan Alambyan; Stephanie Chen; Osmond C Wu; Macym Rizvi; Anthony Hammond; Ciro Ramos-Estebanez
Journal:  Front Neurol       Date:  2017-11-29       Impact factor: 4.003

6.  Tranexamic acid reduces postoperative blood loss in Chinese pediatric patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Zhi-Yao Zou; Li-Xian He; Yun-Tai Yao
Journal:  Medicine (Baltimore)       Date:  2022-03-04       Impact factor: 1.817

7.  Decreased plasma ADAMTS-13 activity as a predictor of postoperative bleeding in cyanotic congenital heart disease.

Authors:  Rosangela P S Soares; Sérgio P Bydlowski; Marcelo B Jatene; Janete Ferreira Hironaka; Antonio Augusto Lopes
Journal:  Clinics (Sao Paulo)       Date:  2013-04       Impact factor: 2.365

8.  Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease.

Authors:  R P S Soares; S P Bydlowski; N M Nascimento; A M Thomaz; E N M Bastos; A A Lopes
Journal:  Braz J Med Biol Res       Date:  2013-04-05       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.